Advertisement

Purpose:

We compared the effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin type A in patients with idiopathic detrusor overactivity.

Materials and Methods:

A total of 45 patients with idiopathic detrusor overactivity refractory to antimuscarinic therapy were randomly allocated to receive 100 U botulinum toxin type A injected into detrusor, suburothelial and bladder base. Videourodynamic studies were performed at baseline and 3 months after treatment. Data collected included symptom score, urgency and incontinence episodes, and urgency severity score. A general satisfaction rating was also assessed as excellent, moderately improved, mildly improved or stationary. A moderately improved or excellent result was defined as successful treatment.

Results:

A total of 15 patients were allocated to each treatment group. A successful result at 3 months was achieved in 14 (93%) patients with detrusor, 12 (80%) with suburothelial and 10 (67%) with bladder base injection. The success rate in the detrusor, suburothelial and bladder base injection groups decreased with time to 67%, 47% and 13% by 6 months, and 20%, 20% and 6.7% at 9 months, respectively (p = 0.0253). Vesicoureteral reflux was not found in any patient after botulinum toxin type A injection. Urgency severity scores improved significantly in all groups after treatment. At 3 months after treatment significant increases in cystometric capacity and post-void residual compared to baseline were found in the detrusor and suburothelial but not in the bladder base group.

Conclusions:

Intravesical injection of 100 U botulinum toxin type A by all 3 methods had a therapeutic effect on idiopathic detrusor overactivity. Bladder base botulinum toxin type A injection relieved urgency sensation but did not increase bladder capacity.

References

  • 1 : European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol2004; 45: 510. Google Scholar
  • 2 : Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology2004; 63: 868. Google Scholar
  • 3 : Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther1980; 212: 16. Google Scholar
  • 4 : A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol2005; 174: 984. LinkGoogle Scholar
  • 5 : Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?. Neurourol Urodyn2005; 24: 231. Google Scholar
  • 6 : Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol2005; 174: 977. LinkGoogle Scholar
  • 7 : Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology2005; 66: 82. Google Scholar
  • 8 : Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology2005; 66: 94. Google Scholar
  • 9 : Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder. BJU Int2001; 87: 774. Google Scholar
  • 10 : Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol1999; 277: C183. Google Scholar
  • 11 : An anatomical description of the male and female urethral sphincter complex. J Urol2004; 171: 1890. LinkGoogle Scholar
  • 12 : Urge incontinence can be a disease of bladder sensors. J Urol1988; 139: 1010. LinkGoogle Scholar
  • 13 : Assessment of the long-term results of subtrigonal phenolisation. Br J Urol1991; 67: 586. Google Scholar
  • 14 : Long-term results of Ingelman-Sundberg denervation procedure for urge incontinence refractory to medical therapy. J Urol2002; 168: 1044. LinkGoogle Scholar
  • 15 : Urinary bladder hyporeflexia and reduced pain-related behavior in P2X3-deficient mice. Nature2000; 407: 1011. Google Scholar
  • 16 : Will suburothelial injection of a small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?. Urology2006; 68: 993. Google Scholar
  • 17 : Botulinum toxin injections into the bladder wall - a morphological evaluation of the injection technique using magnetic resonance imaging. J Urol2006; 175: 415. abstract 1287. LinkGoogle Scholar
  • 18 : Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol2007; 177: 1011. LinkGoogle Scholar

Department of Urology, Buddhist Tzu Chi General Hospital and School of Medicine, Tzu Chi University, Hualien, Taiwan

Advertisement